Alpha emitting radionuclides with medically relevant half-lives are interesting for treatment of tumors and other diseases because they deposit large amounts of energy close to the location of the radioisotope. Researchers at the Cyclotron Institute at Texas A&M University are developing a program to produce 211At, an alpha emitter with a 7.2 h half-life. The properties of 211At make it a great candidate for targeted alpha therapy for cancer due to its short half-life and decay mechanism. Astatine-211 has now been produced multiple times and novel chemistry has been developed for the separation of the At from the Bi target.
Diving Deep on the Periodic Table to Find a Treatment for Cancer
Tuesday, March 1, 2022 - 12:45 to 14:00
Professor Sherry Yennello
Department of Chemistry, Texas A&M University
LMC - Lectures in Modern Chemistry